Bigfoot Biomedical Named to Fast Company’s “World’s Most Innovative Companies” List
Award recognizes Bigfoot’s commitment to delivering innovative technologies that simplify the complexities of diabetes management for people living with insulin-requiring diabetes
MILPITAS, Calif.--(BUSINESS WIRE)--Bigfoot Biomedical (Bigfoot), a leader in developing intelligent connected injection support systems, has been selected as one of Fast Company's 2023 “World’s Most Innovative Companies” in the medical device category. Fast Company is the world’s leading business media brand, with an editorial focus on innovation in technology, leadership, world changing ideas, creativity, and design.
“Our focus on innovation to simplify the complexities of diabetes management for people living with insulin-requiring diabetes is core to our mission, and it’s an honor to see this commitment validated by Fast Company,” said Jeffrey Brewer, CEO of Bigfoot Biomedical. “I’m amazed by the work being done to improve healthcare by fellow honorees on this list and am incredibly proud of the hard work of the Bigfoot team that made this recognition possible.”
Bigfoot was recognized by Fast Company for its Bigfoot Unity® Diabetes Management System, the first and only FDA-cleared dose decision support system based upon continuous glucose monitoring (CGM) data, offering a simple tool for people with diabetes who take multiple daily injections (MDI) of insulin.
“What a strange and thrilling year it has been to honor this year’s Most Innovative Companies. This year’s list compiles some of the most cutting-edge groundbreakers who are changing our world every single day, from legacy organizations like McDonald’s to upstarts like MrBeast and institutions such as NASA. Everyone on this list does something completely, uniquely different, yet, they all have one thing in common: innovation,” said Fast Company editor-in-chief Brendan Vaughan.
The Bigfoot Unity System enables, for the first time, people on multiple daily injections of insulin therapy to get an insulin dose suggestion, on demand, based on CGM data and their doctor’s instructions – helping to take the anxious guesswork out of daily insulin management.
About Bigfoot Biomedical, Inc.:
Bigfoot Biomedical (Bigfoot), headquartered in Milpitas, California, was founded by a team of people with personal connections to type 1 and type 2 diabetes. Bigfoot aims to free people from the burdens of living with insulin-requiring diabetes, improve access, and support health care professionals in optimizing diabetes care. Bigfoot is an unconventional company taking an unconventional approach. Unlike others, Bigfoot looks at insulin therapy holistically, and utilizes services, support, and novel business models. The company partners with healthcare professionals to deliver simple, connected, and comprehensive solutions for the large number of people who have been overlooked by diabetes innovation. Learn more at www.bigfootbiomedical.com and by following us on LinkedIn, Twitter, Instagram, and Facebook.
Bigfoot and Bigfoot Unity are trademarks or registered trademarks of Bigfoot Biomedical, Inc. in the United States of America and other various jurisdictions. All rights reserved.
About Fast Company
Fast Company is the only media brand fully dedicated to the vital intersection of business, innovation, and design, engaging the most influential leaders, companies, and thinkers on the future of business. Headquartered in New York City, Fast Company is published by Mansueto Ventures LLC, along with our sister publication Inc., and can be found online at www.fastcompany.com.
Account Director, Health+Commerce
(260) 336 6202